Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Papi

Showing results (381-390 of 430) with videos related to

Pageof 43
Sort By:
The Lancet. Respiratory Medicine|April 17, 2025
Efficacy, safety, and immunogenicity of the AS01<sub>E</sub>-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trialMichael G Ison, Alberto Papi, Eugene Athan, et al.
American Journal of Respiratory and Critical Care Medicine|March 1, 2023
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive SummaryAlvar Agustí, Bartolome R Celli, Gerard J Criner, et al.
The European Respiratory Journal|March 1, 2023
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive SummaryAlvar Agustí, Bartolome R Celli, Gerard J Criner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 22, 2024
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV SeasonsMichael G Ison, Alberto Papi, Eugene Athan, et al.
Respirology (Carlton, Vic.)|March 1, 2023
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive SummaryAlvar Agustí, Bartolome R Celli, Gerard J Criner, et al.
American Journal of Respiratory Cell and Molecular Biology|December 2, 2020
Rhinovirus-induced CCL17 and CCL22 in Asthma Exacerbations and Differential Regulation by STAT6Teresa C Williams, David J Jackson, Steven Maltby, et al.
The New England Journal of Medicine|June 5, 2023
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil CountsSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
The Lancet. Respiratory Medicine|October 2, 2025
Assessment of the role of small airway dysfunction in relation to exacerbation risk in patients with well controlled asthma (ATLANTIS): an observational studyStanley P Galant, Pauline J M Kuks, Tessa M Kole, et al.
Allergy|November 10, 2025
Cluster Analysis to Identify Distinct Asthma Phenotypes in the ATLANTIS CohortPauline J M Kuks, Tatiana Karp, Jorine E Hartman, et al.
The New England Journal of Medicine|May 22, 2019
Benralizumab for the Prevention of COPD ExacerbationsGerard J Criner, Bartolome R Celli, Christopher E Brightling, et al.
Pageof 43

Showing results (381-390 of 430) with videos related to

Sort By:
Pageof 43
The Lancet. Respiratory Medicine|April 17, 2025
Efficacy, safety, and immunogenicity of the AS01<sub>E</sub>-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trialMichael G Ison, Alberto Papi, Eugene Athan, et al.
American Journal of Respiratory and Critical Care Medicine|March 1, 2023
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive SummaryAlvar Agustí, Bartolome R Celli, Gerard J Criner, et al.
The European Respiratory Journal|March 1, 2023
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive SummaryAlvar Agustí, Bartolome R Celli, Gerard J Criner, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 22, 2024
Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV SeasonsMichael G Ison, Alberto Papi, Eugene Athan, et al.
Respirology (Carlton, Vic.)|March 1, 2023
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive SummaryAlvar Agustí, Bartolome R Celli, Gerard J Criner, et al.
American Journal of Respiratory Cell and Molecular Biology|December 2, 2020
Rhinovirus-induced CCL17 and CCL22 in Asthma Exacerbations and Differential Regulation by STAT6Teresa C Williams, David J Jackson, Steven Maltby, et al.
The New England Journal of Medicine|June 5, 2023
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil CountsSurya P Bhatt, Klaus F Rabe, Nicola A Hanania, et al.
The Lancet. Respiratory Medicine|October 2, 2025
Assessment of the role of small airway dysfunction in relation to exacerbation risk in patients with well controlled asthma (ATLANTIS): an observational studyStanley P Galant, Pauline J M Kuks, Tessa M Kole, et al.
Allergy|November 10, 2025
Cluster Analysis to Identify Distinct Asthma Phenotypes in the ATLANTIS CohortPauline J M Kuks, Tatiana Karp, Jorine E Hartman, et al.
The New England Journal of Medicine|May 22, 2019
Benralizumab for the Prevention of COPD ExacerbationsGerard J Criner, Bartolome R Celli, Christopher E Brightling, et al.
Pageof 43